PHGDH phosphorylation mediated by WNK1 serves as a dual marker of metabolic vulnerability and responsiveness to oxaliplatin treatment
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2525213123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Shaobo Fang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital, Zhengzhou 450003, China. Hauptthemen laut MEDLINE: Oxaliplatin, WNK Lysine-Deficient Protein Kinase 1, Phosphoglycerate Dehydrogenase, Stomach Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Metabolic reprogramming is a fundamental hallmark of cancer progression. However, the oncogenic mechanisms underlying serine metabolism and its impact on chemotherapeutic sensitivity in gastric cancer (GC) remain poorly defined. Here, through integrated metabolomics and 13 C-labeled metabolic flux analysis, we identify marked dysregulation of serine metabolism in GC, primarily driven by increased expression of phosphoglycerate dehydrogenase (PHGDH). Mechanistically, we show that with no lysine kinase 1 (WNK1) phosphorylates PHGDH at Ser349 and Ser371, enhancing its enzymatic activity and protein stability by preventing ubiquitin-mediated degradation. In vivo, WNK1 knockout mice exhibit significantly reduced gastric tumor burden, accompanied by decreased serine levels and disrupted redox balance, supporting the protumorigenic role of the WNK1–PHGDH axis. Clinically, enhanced PHGDH activity, elevated serine levels, and increased glutathione abundance are strongly associated with poor oxaliplatin response in GC patient cohorts, suggesting PHGDH as a potential predictive biomarker for chemotherapy resistance. Together, these findings delineate a WNK1–PHGDH–driven serine metabolic reprogramming axis that promotes redox adaptation and chemoresistance in GC, highlighting its dual value as a mechanistic driver and a therapeutic vulnerability in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital, Zhengzhou 450003, China.
- China-United States (Henan) Hormel Cancer Institute, Jinshui District, Zhengzhou, Henan 450003, China.
- Henan Key Laboratory of Chronic Disease Management, Fuwai Central China Cardiovascular Hospital, Zhengzhou 450000, China.
- Central China Subcenter of National Center for Cardiovascular Diseases, Henan Cardiovascular Disease Center, Fuwai Central-China Cardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou 4…
- Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, China.
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, China.
ORCID-Profile: Simin Zhao, Meiyun Wang, Zigang Dong
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
Zitieren
APA
Fang, S., Jin, G., Yan, M., Song, Y., Zhao, S., Zhang, C., Shao, Y., Zhao, K., Liu, M., Wang, Z., Jia, X., Guo, Q., Guo, M., Wang, M., Guo, Z., & Dong, Z. (2026). PHGDH phosphorylation mediated by WNK1 serves as a dual marker of metabolic vulnerability and responsiveness to oxaliplatin treatment. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2525213123
Vancouver
Fang S, Jin G, Yan M, Song Y, Zhao S, Zhang C, et al. PHGDH phosphorylation mediated by WNK1 serves as a dual marker of metabolic vulnerability and responsiveness to oxaliplatin treatment. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2525213123
BibTeX
@article{Fang2026,
author = {Fang, Shaobo and Jin, Guoguo and Yan, Mingyang and Song, Yanming and Zhao, Simin and Zhang, Chengjuan and Shao, Yang and Zhao, Kexin and Liu, Meng and Wang, Zhenwei and Jia, Xinyang and Guo, Qinxin and Guo, Manman and Wang, Meiyun and Guo, Zhiping and Dong, Zigang},
title = {PHGDH phosphorylation mediated by WNK1 serves as a dual marker of metabolic vulnerability and responsiveness to oxaliplatin treatment},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2525213123}
}
EUVIMED